

Return on Innovation



Global health R&D delivers for Massachusetts



US government (USG) investment in global health R&D has delivered

\$731.1 million

to Massachusetts research institutions*

8,400⁺ new jobs

for Massachusetts†

Massachusetts's top global health R&D institutions by USG funding*

ORGANIZATION	FUNDING
Harvard University	\$135.0 million
Massachusetts General Hospital	\$93.4 million
Beth Israel Deaconess Medical Center	\$89.8 million
Brigham and Women's Hospital	\$82.3 million
University of Massachusetts Medical School	\$80.4 million
Broad Institute	\$44.1 million
Children's Hospital Boston	\$51.8 million

Neglected diseases in Massachusetts†

HIV diagnoses	6,241
Tuberculosis cases	1,916
Malaria cases	388
Chikungunya cases	234
Zika cases	129

Massachusetts industry in global health R&D


AstraZeneca: Waltham
Bristol-Myers Squibb: Cambridge, Devens, Waltham
EMD Serono: Billerica, Rockland
GSK: Cambridge
Merck & Co: Boston

Global health R&D at work in the Bay State



Researchers from Harvard Medical School, Partners In Health, and Boston Children's Hospital have shown that a new commercially developed rapid test for Ebola, performed at the point of care, was as effective as a conventional laboratory-based method. The successful field trial is a potential gamechanger. A test that can accurately diagnose Ebola within minutes provides clinicians with crucial information for treating patients and containing outbreaks.

Massachusetts's top areas of global health R&D by USG funding*



GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES*

89¢ of every dollar
 the USG invests in global health R&D stays within the United States, **supporting the domestic economy.**

USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

200K new US jobs

\$33 BILLION in US economic growth.

*Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007-2015 and for Ebola and select viral hemorrhagic fevers from 2014-2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See www.ghtcoalition.org for full methodology.

†Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See www.ghtcoalition.org for additional details.

‡Centers for Disease Control and Prevention: HIV diagnoses 2008-2016, Tuberculosis cases 2008-2016, Malaria cases 2008-2014, Chikungunya virus disease cases 2014-2017, Zika virus disease cases 2015-2017.

§Source: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. 2017.

¶NTD: neglected tropical disease. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.